Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 79
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more

Conditions: Psychiatric Disorders
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 4
States / cities: Little Rock, Arkansas • Orange, California • Decatur, Georgia + 1 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more

Conditions: Urinary Incontinence, Urgency Urinary
Interventions: Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mania, Bipolar Disorder
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Schizophrenia
Interventions: Xanomeline/trospium chloride; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 13
States / cities: Little Rock, Arkansas • Bellflower, California • Garden Grove, California + 9 more

Conditions: Schizophrenia
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 29 more

Conditions: Schizophrenia
Interventions: Xanomeline/Trospium; Drug
Lead sponsor: Vanguard Research Group; Other
Eligibility: 18 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Texas

Conditions: Healthy
Interventions: Trospium Chloride (Sanctura XR®), Metformin hydrochloride (Glucophage®); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Alzheimer Disease, Agitation
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more

Conditions: Schizophrenia
Interventions: xanomeline and trospium chloride (X/T) therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Costa Mesa, California • San Jose, California • Miami, Florida + 17 more

Conditions: Urgency Urinary Incontinence
Interventions: Trospium, Placebo oral tablet; Drug
Lead sponsor: Becky Clarkson; Other
Eligibility: 60 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: KarXT (xanomeline and trospium); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Interstitial Cystitis, Levator Spasm, Bladder Pain Syndrome
Interventions: Multimodal Bundle Drugs, Operative Cystoscopy, Behavioral health consultation/therapy, Pelvic floor physical therapy, Usual Urogynecologic care, Bladder Instillation, Vaginal estrogen, Methenamine, Amitriptyline/Gabapentin; Drug · Procedure · Behavioral + 1 more
Lead sponsor: Jocelyn Fitzgerald; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: trospium chloride inhalation powder (TrIP), Placebo; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Timeline: 2007
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions: mirabegron, antimuscarinic medication; Drug
Lead sponsor: Astellas Scientific & Medical Affairs, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 75
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more

Conditions: Elderly, Pharmacokinetics, Overactive Bladder
Interventions: Trospium Chloride; Drug
Lead sponsor: Allergan; Industry
Eligibility: 65 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions: Cobenfy KarXT pill (50/20 mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Volunteers
Interventions: KarXT, Midazolam, Fexofenadine, Digoxin; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 147
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Search by objective public record fields.

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

Inflammation in Women With Urgency Urinary Incontinence Treated With Anticholinergics

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

A Study to Evaluate the Effect of KarXT on Urological Safety

Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)